Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2713–2736 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: placebo Clear all

Conditions: Type 2 Diabetes Mellitus
Interventions: Captopril, placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Epidermolysis Bullosa, Pruritus
Interventions: VPD-737, Placebo; Drug · Other
Lead sponsor: Jean Yuh Tang; Other
Eligibility: 13 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Stanford, California

Conditions: Smoking Cessation
Interventions: placebo, varenicline; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 659 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 12
States / cities: Litchfield Park, Arizona • Los Angeles, California • Santa Ana, California + 9 more

Conditions: Cannabis Use, Tobacco Use, Cigarette Smoking
Interventions: THC 30mg, THC 5mg, THC 0mg, Cigarette Full Nicotine, Cigarette Reduced Nicotine; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Severe Hypertriglyceridemia, Mixed Dyslipidaemia
Interventions: Gemcabene, Placebo; Drug
Lead sponsor: NeuroBo Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 48
States / cities: Fort Payne, Alabama • Tucson, Arizona • Beverly Hills, California + 41 more

Conditions: Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
Interventions: BLU-808, Placebo; Drug
Lead sponsor: Blueprint Medicines Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 27
States / cities: Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 23 more

Conditions: Obesity
Interventions: Glucagon, Placebo; Drug
Lead sponsor: AdventHealth Translational Research Institute; Other
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Progressive Supranuclear Palsy
Interventions: BIIB092, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 41 Years to 86 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 13
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 10 more

Conditions: Hypertension, Pure Autonomic Failure, Multiple System Atrophy
Interventions: Losartan, Captopril, Placebo; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Bipolar I Disorder
Interventions: Lithium treatment in combination with a SGA (Second Generation Antipsychotic), Placebo/Adjunctive SGA treatment; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 12 Years to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Glen Oaks, New York

Conditions: Overweight, Diabetes Mellitus Type 2 in Obese
Interventions: P11187, Placebo; Drug
Lead sponsor: Piramal Enterprises Limited; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Urinary Retention, Prostatic Hyperplasia, Benign Prostatic Hypertrophy
Interventions: Alfuzosin (SL770499); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 55 Years and older · Male only
Enrollment: 1,522 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 35
States / cities: Huntsville, Alabama • La Mesa, California • San Bernardino, California + 32 more

Conditions: Peripheral Nervous System Diseases, HIV Infections
Interventions: Smoked Marijuana; Drug
Lead sponsor: Center for Medicinal Cannabis Research; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Tobacco Dependence
Interventions: bupropion + nicotine gum, Active bupropion-Placebo gum, Placebo bupropion-Placebo gum; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 608 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2002
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Depressive Disorder, Major, Post Traumatic Stress Disorder
Interventions: Ketamine, Perampanel, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Schizophrenia
Interventions: D-cycloserine, Placebo, Cognitive Remediation; Drug · Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Primary Biliary Cholangitis
Interventions: EDP-305 1 mg, EDP-305 2.5 mg, Placebo; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 40
States / cities: Dothan, Alabama • Little Rock, Arkansas • Coronado, California + 28 more

Conditions: Essential Tremor of the Upper Limb
Interventions: NT 201, Placebo; Drug
Lead sponsor: Merz Pharmaceuticals GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 9
States / cities: Tampa, Florida • Omaha, Nebraska • Las Vegas, Nevada + 6 more

Conditions: Acute Kidney Injury
Interventions: BCT197 Part A, Placebo, BCT197 Part B; Drug
Lead sponsor: Mereo BioPharma; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 6
States / cities: Orange, California • Saginaw, Michigan • Lincoln, Nebraska + 3 more

Conditions: Symptomatic Vitreomacular Adhesion
Interventions: ocriplasmin, placebo; Drug
Lead sponsor: ThromboGenics; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Brain Injuries, Traumatic
Interventions: Sodium Lactate, Placebo; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Alzheimer Disease
Interventions: Dimebon 20 mg po TID, Placebo po TID; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 21
States / cities: Phoenix, Arizona • Costa Mesa, California • Encino, California + 17 more

Conditions: Postoperative Pain
Interventions: Percutaneous peripheral nerve stimulation, Sham stimulation; Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: La Jolla, California • San Diego, California

Conditions: Influenza
Interventions: FluMist, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Miami, Florida

Search by objective public record fields.

Measurement of Eye Blood Flow and Renal Function in Healthy and Diabetic Patients

Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients

Randomized Study Comparing the Efficacy and Safety of Varenicline Tartrate to Placebo in Smoking Cessation When Subjects Are Allowed to Set Their Own Quit Date

Effect of Cannabis on Cigarette Use Behavior

A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia

Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)

Effect of Prolonged (72 Hour) Glucagon Administration on Energy Expenditure in Healthy Obese Subjects

Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy

Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure

Study of the Efficacy of Adjunctive Lithium Treatment for the Treatment of Psychotic Mania

Determination of Safety,Tolerability,Pharmacokinetics,Food Effect& Pharmacodynamics of Single & Multiple Doses of P11187

Clinical Trial in Males With BPH (Enlarged Prostate)

Marijuana for HIV-Related Peripheral Neuropathy

Bupropion Alone or Combined With Nicotine Gum

Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response

D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis

A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm

Safety & Efficacy of BCT197 in Patients Undergoing Cardiac Surgery

Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin Studies

Exogenous Sodium Lactate Infusion in Traumatic Brain Injury (ELI-TBI)

A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease

Percutaneous Peripheral Nerve Stimulation (Neuromodulation) for Postoperative Analgesia

Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults